This therapeutic approach has had a major impact on haematological malignancies and solid tumours (such as ERBB2-positive breast cancers or EGFR-positive colorectal carcinomas) via a range of beneficial effects, including growth arrest, induction of apoptosis, inhibition of angiogenesis, etc 47. Here, ERBB2 is linked to breast carcinoma.